Based on data from the present study and others, BRAF-mutant GIST does not respond well to KIT TKIs but does respond well to combination BRAF and MEK inhibition, as is seen in other BRAF-driven cancers, such as melanoma. Here, KIT is linked to gastrointestinal stromal tumor.